Filing Flows › UroGen Pharma (URGN) › Q4 2025
UroGen Pharma (URGN) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 2, 2026
UroGen Pharma (URGN) reported revenue of $37.8M for the fourth quarter 2025 (Q4 2025), +54% from a year earlier and +38% from the quarter before. Operating margin was -50.5%, net loss $26.4M (69.7% of revenue).
UroGen Pharma, Q4 2025: revenue $37.8M (+54% year over year), operating margin -50.5%, net loss $26.4M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.8M | +38% | +54% |
| Operating profit | −$19.1M | — | — |
| Net earnings | −$26.4M | — | — |
| Operating cash flow | −$38.3M | — | — |
What changed
Revenue was $37.8M in Q4 2025, up 54% year over year and up 38% from the previous quarter. Jelmyto was the largest line at 63% of revenue.
Gross margin was 91.3%, up 1.4 points from a year earlier. Operating costs exceeded revenue by $19.1M, an operating margin of -50.5%. Operating expenses grew 8% against revenue growth of 54%. The fastest-growing cost line was SG&A (+13%). The quarter ended with a net loss of $26.4M, narrower than the previous quarter's $33.3M loss.
Operating cash flow was −$38.3M. Non-cash charges added back $75K of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $15.2M. Capital expenditures of $17K exceeded it, leaving free cash flow of −$38.3M.
Questions
What was UroGen Pharma's revenue in the fourth quarter 2025?
UroGen Pharma (URGN) reported revenue of $37.8M for the fourth quarter 2025 (Q4 2025), +54% from a year earlier and +38% from the quarter before.
Was UroGen Pharma profitable in the fourth quarter 2025?
Operating loss was $19.1M (-50.5% of revenue) and net loss $26.4M.
Source: UroGen Pharma 10-K on SEC EDGAR.